Sonidegib for the Treatment of Advanced Basal Cell Carcinoma

Frontiers in Oncology
Gabriella BrancaccioGiuseppe Argenziano

Abstract

Basal cell carcinoma (BCC) accounts for almost 80% of skin cancers, and its healthcare workload burden is substantial within dermatology departments. Although most BCCs are small, well-defined tumors amenable of surgery or conservative procedures, in a small proportion of patients, BCCs can progress to an advanced stage including locally advanced BCC. The goal of the clinician in the treatment of BCC should be the right therapeutic approach at diagnosis, and different guidelines propose treatment strategies in order to prevent relapses or disease progression. In case of unresectable and untreatable BCC with radiotherapy, the first-choice medical therapy is Hedgehog-GLI (HH) pathway inhibitors. Sonidegib was approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) as a first-line treatment for adult patients with locally advanced BCC, becoming the second HH pathway inhibitor receiving approval after vismodegib. In this review, data on pharmacology, safety, tolerability, and efficacy of sonidegib are summarized and compared to those of vismodegib. Lastly, indications on the management of advanced basal cell carcinoma based on author's clinical experience are provided.

References

Feb 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard A GrahamPatricia M Lorusso
Apr 20, 2011·Nature Reviews. Genetics·Philip W InghamClaudia Seger
Jul 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LorussoRichard A Graham
Feb 14, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jordi RodonAlain C Mita
May 13, 2014·Cancer Chemotherapy and Pharmacology·Markus ZollingerPiet Swart
Jun 10, 2010·ACS Medicinal Chemistry Letters·Shifeng PanMarion Dorsch
Sep 11, 2014·Annals of Neurosciences·Zia ChoudhryNusrat Jahan Mobassarah
May 20, 2015·Journal of the American Academy of Dermatology·Aleksandar SekulicUNKNOWN ERIVANCE BCC investigators
Sep 2, 2015·Drugs·Celeste B Burness
Jan 20, 2016·CPT: Pharmacometrics & Systems Pharmacology·T LuJ Y Jin
Jun 10, 2016·British Journal of Clinical Pharmacology·Jocelyn ZhouDalila Sellami
Jan 27, 2017·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Heidi J EinolfSam Rebello
Feb 22, 2017·The British Journal of Dermatology·J A C VerkouterenT Nijsten
Feb 7, 2018·Cancer Treatment Reviews·Michael R MigdenJohn T Lear
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Richard L Carpenter, Haimanti Ray
Mar 14, 2019·The British Journal of Dermatology·Z C VenablesI M Leigh
Jul 10, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ketty PerisUNKNOWN European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Rese
Jan 29, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·R DummerR J J Grob

❮ Previous
Next ❯

Citations

Aug 23, 2021·Biochimica Et Biophysica Acta. Molecular Cell Research·Xin YangShen Yue

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
biopsy
pregnancy test

Software Mentioned

mRECIST

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.